A drug that boosts platelets may speed recovery after stem cell transplants in kids with thalassemia
NCT ID NCT07003269
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This observational study tests whether hetrombopag, a platelet-boosting drug, can safely speed platelet recovery in children with thalassemia who receive a half-matched (haploidentical) stem cell transplant. Thirty children aged 2 to 17 will be followed for 28 days after transplant to track how quickly their platelet counts rise and how many transfusions they need. The study also monitors for side effects like bleeding or blood clots.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hetrombopag, a drug that stimulates platelet production, given as a shot after stem cell transplant
- What this could lead to
- If hetrombopag proves safe and effective, it could speed platelet recovery and reduce the need for platelet transfusions in children with thalassemia after a stem cell transplant.
- What could go wrong
- This is a small observational study with only 30 children, so results may not apply to everyone. The drug may cause side effects like bleeding or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The Department of Hematology of Haikou People's Hospital accepts children with severe thalassemia aged 2 - 17 years old for haploidentical hematopoietic stem cell transplantation.
- Ages
-
2 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosed with severe thalassemia via thalassemia gene testing, transfusion history, and complete blood count (CBC). * Pediatric patients aged 2-17 years. * Consented to haploidentical transplantation and evaluated by the transplant team as having no transplant contraindications. Exclusion Criteria: * Presence of a fully matched donor with refusal of haploidentical transplantation. * Donor or recipient with transaminase levels \>2× the upper limit of normal (ULN). * Positive hepatitis B DNA test result. * Active infection at the time of enrollment. * Donor-specific antibodies (DSA) \>5,000 and unable to decrease below 3,000 after antibody therapy. * Presence of transplant contraindications as assessed by the transplant team.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thalassemia in children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou, Hainan, 570208, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.